Literature DB >> 16039528

Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation.

Jae Suk Ahn1, Mala L Radhakrishnan, Marina Mapelli, Sungwoon Choi, Bruce Tidor, Gregory D Cuny, Andrea Musacchio, Li-An Yeh, Kenneth S Kosik.   

Abstract

Cyclin-dependent kinase 5 (Cdk5) is widely viewed as a possible target for a wide variety of neurological disorders. One pathological role attributed to Cdk5 is the abnormal phosphorylation of tau that may lead to the neuronal inclusions known as neurofibrillary tangles. A high through-put screen for inhibitors of Cdk5-mediated phosphorylation of tau resulted in three compounds with distinct mechanisms of action. One compound is competitive with ATP and has a high affinity for the Cdk5 ATP binding pocket. The second compound also competes with ATP, is noncompetitive with tau, and (uniquely among this class of inhibitors) displaces adjacent amino acid residues to make room for the nitrophenyl group. A third compound did not compete with ATP, but did compete with tau at low concentrations of tau. The SAR and charge optimization derived from cocrystals of the two ATP competitors along with cocrystals of three other ATP competitors map out the importance of filling and properly charging different regions of the ATP binding pocket. Taken together, this analysis shows how the structure of Cdk5 constrains the space of potential inhibitors and reveals a pocket unfilled in all of the structures. These leads could be a starting point for structure-based drug design of more potent and selective inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039528     DOI: 10.1016/j.chembiol.2005.05.011

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  21 in total

1.  Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants.

Authors:  Erin E Congdon; Sohee Kim; Jonathan Bonchak; Tanakorn Songrug; Anastasios Matzavinos; Jeff Kuret
Journal:  J Biol Chem       Date:  2008-03-21       Impact factor: 5.157

2.  Identification and characterization of a novel phosphoregulatory site on cyclin-dependent kinase 5.

Authors:  Brett Lee Roach; Jordan Matthew Ngo; Clariss Limso; Koyinsola Bolutife Oloja; Deepali Bhandari
Journal:  Biochem Biophys Res Commun       Date:  2018-09-11       Impact factor: 3.575

3.  Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems.

Authors:  Mala L Radhakrishnan; Bruce Tidor
Journal:  J Chem Inf Model       Date:  2008-05-27       Impact factor: 4.956

Review 4.  Therapeutic strategies for Alzheimer's disease.

Authors:  Donna M Barten; Charles F Albright
Journal:  Mol Neurobiol       Date:  2008-06-26       Impact factor: 5.590

5.  Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.

Authors:  Joydev K Laha; Xuemei Zhang; Lixin Qiao; Min Liu; Snigdha Chatterjee; Shaughnessy Robinson; Kenneth S Kosik; Gregory D Cuny
Journal:  Bioorg Med Chem Lett       Date:  2011-02-03       Impact factor: 2.823

6.  Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.

Authors:  Arindam Chatterjee; Stephen J Cutler; Robert J Doerksen; Ikhlas A Khan; John S Williamson
Journal:  Bioorg Med Chem       Date:  2014-09-28       Impact factor: 3.641

7.  Amino acid sequence conservation of the algesic fragment of myelin basic protein is required for its interaction with CDK5 and function in pain.

Authors:  Andrei V Chernov; Albert G Remacle; Swathi K Hullugundi; Piotr Cieplak; Mila Angert; Jennifer Dolkas; Veronica I Shubayev; Alex Y Strongin
Journal:  FEBS J       Date:  2018-08-27       Impact factor: 5.542

Review 8.  Structure-based discovery of cyclin-dependent protein kinase inhibitors.

Authors:  Mathew P Martin; Jane A Endicott; Martin E M Noble
Journal:  Essays Biochem       Date:  2017-11-08       Impact factor: 8.000

9.  Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

Authors:  Ernst Schonbrunn; Stephane Betzi; Riazul Alam; Mathew P Martin; Andreas Becker; Huijong Han; Rawle Francis; Ramappa Chakrasali; Sudhakar Jakkaraj; Aslamuzzaman Kazi; Said M Sebti; Christopher L Cubitt; Anthony W Gebhard; Lori A Hazlehurst; Joseph S Tash; Gunda I Georg
Journal:  J Med Chem       Date:  2013-05-06       Impact factor: 7.446

10.  New directions for frontotemporal dementia drug discovery.

Authors:  John Q Trojanowski; Karen Duff; Howard Fillit; Walter Koroshetz; Jeff Kuret; Diane Murphy; Larry Refolo
Journal:  Alzheimers Dement       Date:  2007-09-10       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.